ITF Health > Program > Speakers  > Gene Dantsker
Share
linkedin twitter facebook email

 

Gene Dantsker    
   

 

Save

Save

Bio

GENE DANTSKER, QUALCOMM LIFE
DIRECTOR BUSINESS DEVELOPMENT

Gene Dantsker is Director of Business Development at Qualcomm Life. Prior to this role, Dr. Dantsker worked across the spectrum of sensor, therapy and diagnostic technology solutions with broad experience in semiconductor, medical and biotech businesses. Dr. Dantsker was Senior Technical Staff Member at TRW, Inc., Space and Electronics Division where he was responsible for design, fabrication, and integration of microelectronics for space/satellite applications. Subsequently he co-founded Nanostream, Inc., a biotech company and provider of high-throughput bio-analytical instruments to companies involved in drug discovery and development. As VP of Technology, Gene was co-inventor and developer of Nanostream’s core technologies based on polymer MEMS microfluidics and converted them into commercial products purchased by leading pharmaceutical companies. Gene then served as CEO and CTO of Adnavance Technologies, Inc., a provider of ultra-sensitive medical molecular diagnostic products, operating out of the US and Canada. Gene also served on the Board of Directors of D-Wave Systems, a pioneer in Quantum Computing, with leading Silicon Valley VCs, as well as heavily consulted the company in business development, general and IP strategy, growth strategy and operational infrastructure. Gene subsequently provided business development support for the US branch of Nitto Denko, a leading supplier of diversified polymer-film products based in Osaka, Japan. He holds B.S. degrees in Physics and Mathematics from the University of Maryland, M.A. and Ph.D. in Physics from the University of California at Berkeley, and an MBA from San Diego State University, where he was class valedictorian. He is an inventor on over 25 patents.

Presentation abstract

INTERNET OF MEDICAL THINGS FOR INTELLIGENT CARE

Modern health care is undergoing an unprecedented shift from volume-driven to value-driven medicine, characterized by outcomes-based payment models and enabled by disruptive technologies that are decentralizing health care and engaging the patient. Access to the patient is empowered both via the evolving pervasive communication infrastructure as well as a plethora of widespread communication-enabled medical devices called the Internet of Medical Things (IOMT). As a result, the point of care is shifting and now spans the entire acuity spectrum, from hospital to home and points in between. Offerings in therapeutics and diagnostics are shifting toward those that incorporate compliance and outcomes via real world data captured from the patients’ interaction with digitally-enabled drug delivery systems, diagnostics and biometrics, resulting in value models for providers, manufacturers and payers to enact actionable visibility into patient populations that are lowering costs and improving targeted delivery of healthcare.
 

 

Back to program

Back to speakers

 

Copyright imec 2017